Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank GlaxoSmithKline for funding the studies (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]), Bob Gagnon for his statistical analyses of the PD data and Leigh O’Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, for medical writing support (funded by GSK).

Disclosure statement

A. D., R. G. K., N. O. K., G. F-B., A. A., H. D. B., and T. C. are employees, and hold stocks/shares, in GSK. M. B. is an employee of GSK and holds stocks/shares in GSK, Celgene and Abbott. GJR participated in consultancy, advisory boards or data and safety monitoring committee for AbbVie, Actinium, Agios, Astex, Astellas, AstraZeneca, Bayer, Bluebird Bio, Blueprint Medicines, Celgene, Daiichi Sankyo, GSK, Helsinn, Janssen, Jasper Therapeutics, Jazz, Novartis, MEI Pharma, Mesoblast, Otsuka, Pfizer, Roche/Genentech, Sandoz, and Takeda. G. S. reports participation on advisory boards or data and safety monitoring committee for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Helsinn Healthcare, Hoffmann–La Roche, Janssen–Cilag, Novartis and Takeda, institutional funding and research from Celgene, Hoffman–La Roche, Janssen–Cilag and Novartis and personal fees from Abbvie, Astellas, Celgene, Janssen-Cilag and Hoffman–La Roche. K. Y. reports consulting fees or advisory role for AbbVie, Astex, Novartis, Pfizer, Celgene, Hoffman–La Roche, Otsuka, Paladin, Shattuck Labs, TaiHo and Takeda and research funding from Astex, Forma Therapeutics, Geron, Janssen, Jazz, Medimmune, Novartis, Onconova and Roche/Genentech. A. H. W. is an employee of the Walter and Eliza Hall Institute, reports research funding from Abbvie, Amgen, AstraZeneca, Celgene, Novartis, Servier and Hoffman–La Roche, honoraria and participation on advisory boards or data and safety monitoring committee for Abbvie, Amgen, Astellas, AstraZeneca, Celgene, Genentech, Janssen, MacroGenics, Novartis, Pfizer and Servier, as well as consulting fees for Servier. A. V. holds stocks/shares in Stelexis; there are no conflicts of interest with this study. G. B. participated in advisory boards or data and safety monitoring committee for Takeda and Janssen. A. F. B. reports consulting fees from AbbVie, Astellas, Celgene, Incyte, Janssen, Jazz Pharmaceutical, Mundipharma, Hoffman–La Roche and Pfizer; honoraria for educational events for AbbVie, Astellas, Celgene, Hoffman–La Roche, Incyte, Jazz Pharmaceutical, Novartis, Pfizer; participation on advisory boards or data and safety monitoring committee for Abbvie, Astellas, Celgene and Hoffman–La Roche and research funds from Novartis and Janssen. H. P. M. has nothing to declare.

Additional information

Funding

This work was supported by GlaxoSmithKline (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]).